41 results about "Aminoglycoside" patented technology

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

The invention relates to polystyrene cation exchange resin as well as a preparation method and application thereof. The preparation method comprises the following steps: dissolving a dispersing agent in a solvent to obtain a dispersed phase for suspension polymerization reaction, uniformly mixing a reaction monomer, a cross-linking agent, a pore-foaming agent and an initiator, and carrying out suspension polymerization reaction under segmented stirring and segmented temperature change to prepare copolymer microspheres; and putting the dried microspheres into a reaction kettle, swelling, carrying out sulfonation reaction through a variable temperature program on the basis to obtain sulfonated microspheres, and carrying out alkali exchange reaction on the sulfonated microspheres to obtain the final product cation exchange resin. Compared with the prior art, the cation exchange resin preparation method provided by the invention has the characteristics of simple and feasible process, easiness in large-scale production, low cost, high specific surface area, high adsorption capacity and high separation efficiency, and is especially suitable for separating and purifying substances containing amino groups or aminoglycosidic bonds.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

Provided herein are aminoglycoside compounds, such as compounds of Formula (I) and Formula (III), and pharmaceutically acceptable salts thereof, useful as therapeutic and / or prophylactic agents. The compounds may be useful in treating a bacterial infection in a subject, for example a Gram-negative bacterial infection. Also provided herein are methods for preparation of such compounds.

The invention discloses a composite biological agent, a preparation method thereof and application of the composite biological agent in promotion of shellfish growth or shellfish fattening. The compound biological agent is prepared from the following components in parts by weight: 4 to 8 parts of glucosamine, 1 to 3 parts of yeast, 1 to 4 parts of sodium tripolyphosphate, 5 to 50 parts of clostridium ethanol protein and 45 to 75 parts of compound algae. The compound biological agent can remarkably improve the fatness of shellfish, increase the meat percentage and improve the growth speed of the shellfish.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

The present invention relates to compositions and methods for manufacturing an adjuvant comprising an aminoalkyl glucosaminide phosphate compound or glucopyranosyl lipid adjuvant using a microfluidic device and to related aspects.

The invention provides a method for preparing micromolecular glucosamine peptide by utilizing leftover materials of aquatic products. The method comprises the following three steps: firstly, treating raw materials through alkaline hydrolysis, and removing impurities; secondly, chitinase, deacetylase and collagenase are added at a certain temperature for enzymolysis, and the raw materials are converted into micromolecular collagen peptide; and finally, carrying out activated carbon adsorption, ultrafiltration membrane filtration and heating evaporation concentration to obtain a high-purity glucosamine peptide solution. The method is efficient, environment-friendly and low in cost, waste generated in the aquatic product processing process can be fully utilized and converted into micromolecular amino glycopeptides with commercial value, cyclic utilization of resources is promoted, and the method has high sustainable development significance and wide industrial application prospects.

The present invention includes novel molecules and methods of using an amphiphilic kanamycin molecule having substitutions at the O-4″, O-6″, or O-4″ and O-6″ positions having reduced antimicrobial activity for targeting Connexin Hemichannels.

The invention discloses aminoglycoside sulfate modified aqueous battery electrolyte as well as a preparation method and application thereof. The battery electrolyte comprises a zinc ion solution and a modified additive, the modified additive is aminoglycoside sulfate, and the concentration of the modified additive in the electrolyte is 0.001 mol / L to 0.1 mol / L; the concentration of zinc ions in the electrolyte is 1-4 mol / L. The electrolyte is obtained after the raw materials including the zinc ion solution and the modified additive are fully mixed and dissolved. According to the electrolyte, aminoglycoside sulfate is adopted as a modifier, a hydrogen bond network in a solution is destroyed, the activity of water is limited, a solvation structure of zinc ions is changed, meanwhile, zinc is induced to be uniformly deposited on the surface of a zinc metal negative electrode, and a water-poor interface protection layer is constructed, so that the side reaction of the zinc metal negative electrode is greatly inhibited; according to the zinc ion secondary battery prepared based on the electrolyte, the cycling stability and the rate capability of the battery are effectively improved, and the performance requirement of a power battery can be met.

Disclosures herein are directed to methods of regenerating cardiomyocytes in heart tissue damaged as a result heart failure in a subject by administering one or more aminoglycosides to a subject in need thereof. Accordingly, disclosures herein are also toward methods of administering one or more aminoglycosides to treat heart failure in a subject in need thereof.

The present disclosure relates to novel methods for preparing antibacterial aminoglycoside compounds, as well as to related intermediates, and crystal forms thereof, useful in such methods.

# imgabs0 # provides herein aminoglycoside compounds, such as compounds of Formula (I) and Formula (III), and pharmaceutically acceptable salts thereof, for use as therapeutic and / or prophylactic agents. The compounds are useful in the treatment of bacterial infections in a subject, such as gram-negative bacterial infections. Also provided herein are methods of making such compounds.

To provide methods for preparing antibacterial sisomicin-type aminoglycoside compounds.SOLUTION: The present disclosure relates to novel methods for preparing antibacterial sisomicin-type aminoglycoside compounds, as well as, to related intermediates and crystal forms of the intermediates useful in such methods. The present disclosure provides processes for preparing compounds of formula (9), which includes plazomicin, that are scalable, reproducible at a commercial scale, and with good yields. These processes comprise reactions that can provide novel intermediate compounds obtained through experimentation and development of new combinations of reaction conditions. The processes may also comprise crystallization of certain intermediates. The crystallization of these particular intermediates unexpectedly contributes to improvements in purification (e.g., lower impurities), and can simplify the purification compared to prior methods of purification.SELECTED DRAWING: Figure 1

This invention provides a small molecule inhibitor targeting the FcεRIγ subunit and its application. It discovers that erythrophenol can act as a small molecule inhibitor targeting the FcεRIγ subunit, thereby inhibiting the occurrence of allergic reactions. This invention confirms the direct binding interaction between erythrophenol and the FcεRIγ subunit using SPR and CETSA techniques, revealing that erythrophenol can target and inhibit the FcεRIγ subunit. Furthermore, this invention finds that erythrophenol can significantly inhibit the release of IgE signal-induced β-aminoglycosidase in mast cells, exhibiting a significant ability to inhibit IgE signal-mediated mast cell degranulation and suppress mast cell activation-mediated allergic reactions. This fully demonstrates that erythrophenol, as an inhibitor targeting the FcεRIγ subunit, holds promise as the first inhibitor to induce FcεRIγ subunit degradation in anti-type I allergic diseases, and has broad application prospects for further use in anti-allergy treatment.

Provided herein are aminoglycoside compounds useful as therapeutic and / or prophylactic agents, such as compounds of formula (I) and formula (III), and pharma- ceutically acceptable salts thereof. The compounds may be useful for treating bacterial infections, such as gram-negative bacterial infections, in subjects. Methods for preparing such compounds are also provided herein. TIFF2025509208000208.tif88168

Fluoroquinolones and aminoglycoside ion-paired crystalline formulations have been developed which bypass the need for frequent dosing. The crystal formulations are made by anionic ion-pairing. These crystal formulations have a slower and more uniform rate of dissolution than the amorphous or other crystalline forms of fluoroquinolones and aminoglycosides so can be suspended in aqueous solution for sustained release. Examples demonstrate ion-paired crystals of moxifloxacin and besifloxacin.

The present invention provides novel aminoglycosides (e.g., compounds of formulae A, B, I, I *, III, or III *, including compounds represented by formulae Ia, I * *, I * a, I * b, IIIa, III * *, III * a, and III * b) designed to exhibit termination codon mutation readout activity represented by the formulae defined in the specification. The invention also provides pharmaceutical compositions comprising the novel aminoglycosides, and their use in the treatment of genetic diseases and disorders, such as diseases and disorders associated with termination codon mutations.

The present invention provides a therapeutic combination for use in treating an infection with a pathogen. The therapeutic combination comprises an aminoglycoside antibiotic; and a nucleic acid monoalkylating agent that substitutes a single nucleotide of a nucleic acid with an alkyl group, wherein the therapeutic combination provides an enhanced suppression of a pathogen when compared with an otherwise identical composition lacking said aminoglycoside antibiotic; or wherein the therapeutic combination provides an enhanced suppression of a pathogen when compared with an otherwise identical composition lacking said nucleic acid monoalkylating agent; and kits for performing said method.

The present invention relates to a the genetically engineered multidrug-resistant reporter V. cholera strain BLF-1Vc which has been constructed and laboratory tested for rapid and robust screening of natural and synthetic molecules for inhibition of enzymes involved in β- lactams, aminoglycosides and macrolide antibiotic resistance and determine its antibiotic 5 potentiating, synergistic or novel antibacterial property. The reporter strain disclosed herein can also be used for testing novel drugs and antimicrobial agents for its efficacy against multidrug resistant clinical isolates. The present invention also discloses a method for preparing a multidrug-resistant reporter microorganism and a kit for detecting antibiotic resistance or screening antimicrobial compounds, comprising the genetically engineered 0 multidrug-resistant reporter V. cholera strain BLF-1Vc.

To provide a combination therapy of an antibiotic and an alkylating agent, and uses thereof as a medicament and for the control of pathogens.SOLUTION: The present invention provides a therapeutic combination for use in treating an infection with a pathogen. The therapeutic combination comprises an aminoglycoside antibiotic and a nucleic acid monoalkylating agent that substitutes a single nucleotide of a nucleic acid with an alkyl group, wherein the therapeutic combination provides an enhanced suppression of a pathogen when compared with an otherwise identical composition lacking the aminoglycoside antibiotic, or wherein the therapeutic combination provides an enhanced suppression of a pathogen when compared with an otherwise identical composition lacking the nucleic acid monoalkylating agent, and kits for executing the method.SELECTED DRAWING: None

Modified aminoglycoside compounds represented by Formula I as defined and described in the specification are provided. The modified aminoglycosides feature a diamine-containing functional moiety at one or more of positions 3′, 4′ and 6′. Uses of the modified aminoglycosides as antimicrobial (e.g., antibacterial) agents, and in treating medical conditions associated with microorganisms, are also provided.

Antibiotic compounds that are reaction products of an antibiotic molecule and a cross-linkable silane molecule are provided which are useful for incorporation into a liquid base coating material. The antibiotic molecule may be a fluoroquinolone, penicillin, cephalosporin, tetracycline, macrolide and / or aminoglycoside, while the cross-linkable silane molecule may be an epoxy-functionalized silane, an aldehyde-functionalized silane and / or a halogenated silane. Coating formulations including the antibioitic compounds and coated substrates which are coated with such coating formulations are also provided.

Described herein are compositions, methods, and kits for detecting antibiotic resistance genes in a sample, such as a wound swab. One embodiment described herein is primer pairs and probes for individual or multiplex polymerase chain reaction (PCR) based assays for the detection of one or more antibiotic resistance gene targets comprising resistance to molecularly characterized extended-spectrum β-lactamases (MESBLs); extended-spectrum β-lactamases (ESBLs); carbapenemase; AmpC β-lactamase; β-lactamase; lincosamide, macrolide, streptogramin; trimethoprim; macrolides; methicillin; colistin; sulfonamide; tetracycline; vancomycin; nitroimidazole; quinolone; or aminoglycoside.

The present disclosure generally relates to a method for reducing the toxicity of inhaled polymyxins as a therapeutic agent comprising the step of co-administration of an aminoglycoside; a method for improving the aerosolization of an aminoglycoside comprising the step of combination formulation with a polymyxin; and a process for manufacturing a dry powder composition comprising a polymyxin and aminoglycoside. Pharmaceutical compositions and methods of treatment for lung infections are within the scope of this invention.

The invention discloses an integrated intelligent response baicalein metal supramolecular implantation device and a preparation method thereof. The integrated intelligent response baicalein metal supramolecular implantation device comprises a metal matrix, a supramolecular network layer formed on the surface of the metal matrix, and aminoglycoside antibiotics loaded on the supramolecular network layer, the supramolecular network layer is formed by chelating a catechol structure of baicalein and metal of the metal matrix. The preparation method comprises the following steps: respectively preparing an ethanol solution of baicalein and an aqueous solution of aminoglycoside antibiotic; mixing the ethanol solution of baicalein and the aqueous solution of aminoglycoside antibiotic, and carrying out ultrasonic dispersion; and soaking a metal matrix in the mixed solution, placing the metal matrix in a shaking table, and carrying out an in-situ reaction for 12-96 hours to obtain the baicalein metal supramolecular implantation device. The baicalein metal supramolecular implantation device can release antibiotics as required in vivo, and has good anti-inflammatory, antibacterial and hemostatic effects.

Fluoroquinolones and aminoglycoside ion-paired crystalline formulations have been developed which bypass the need for frequent dosing. The crystal formulations are made by anionic ion-pairing. These crystal formulations have a slower and more uniform rate of dissolution than the amorphous or other crystalline forms of fluoroquinolones and aminoglycosides so can be suspended in aqueous solution for sustained release. Examples demonstrate ion-paired crystals of moxifloxacin and besifloxacin.

Described herein is a general solution to 1,2-cis-amino-glycoside synthesis through an iron-catalyzed, exclusively 1,2-cis-selective glycal aminoglycosylation via cooperative atom transfer catalysis. Further described is a 1,2-cis-selective glycal aminoacyloxylation method for 2-amino saccharide synthesis. The methods are effective for a wide variety of glycosyl donors with consistently high stereoselectivity and excellent functional-group compatibility, which facilitates late-stage amino group incorporation for complex-carbohydrate and other biologially-related molecule synthesis.